Shopping Cart 0
Cart Subtotal
AED 0

Autoimmune Disease Therapeutics Market by Drug Class (Anti-Inflammatory, Antihyperglycemics, NSAIDs, Interferons, and Others), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, , Inflammatory Bowel Disease and Others) and Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Store): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 19708

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 33012

Details

According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global autoimmune disease therapeutics market was valued at USD 109,833 million in 2017, and is expected to reach USD 153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
 
Autoimmune disease therapeutics include different types of drugs such as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, immune suppressants, corticosteroids, beta-blockers, and others. The demand for autoimmune disease therapeutics is estimated to increase during the forecast period owing to surge in prevalence of autoimmune disease, advancement in screening & diagnosis procedures, and wide availability of advanced therapeutics. Moreover, strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others is expected to further boost the market growth.
 
Based on drug class, the global autoimmune disease therapeutics market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017, and is expected to maintain its dominance during the forecast period owing to increase in demand for anti- inflammatory drugs, launch of newer anti- inflammatory drugs with the supportive reimbursement policies for usage of advanced anti- inflammatory drugs in some countries. Moreover, expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab, and others, is estimated to further influence the market growth.
 
Based on indication, the market is classified as rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. Rheumatic disease segment accounted for a major share in 2017 and is expected to remain dominant during the forecast period owing to surge in prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, polymyalgia rheumatica and others, wide availability of advanced therapeutics for treatment of rheumatic disease, availability of advanced therapeutics for the treatment of these diseases.
 
According to sales channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online stores. Online providers segment is expected to experience rapid growth during the forecast period owing to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users. On the other side, drug store & retail pharmacy segment is estimated to be the major revenue contributor due to massive presence of these pharmacies.
 
Key Findings of theAutoimmune Disease Therapeutics Market:
Based on indication, the rheumatic disease segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
Based on sales channel, the online stores segment is expected to experience rapid growth and is projected to grow at a CAGR of 6.8% during the forecast period 2018-2025.
Depending on drug class, the anti-inflammatory segment accounted for nearly half of the global market share in 2017, and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period.
North America accounted for a major market share in 2017, and is expected to remain dominant throughout the forecast period. Higher prevalence of autoimmune disease, early diagnosis, easy availability of advanced therapeutics, strong presence of key players, favorable reimbursement in healthcare system, and higher number of trained medical professionals are key drivers of the North America autoimmune disease therapeutics market. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period owing to increase in number of target population, rise in adoption of therapeutics with development in healthcare infrastructure.
READ MORE

Table Of Content

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1. Key findings of the study

 

2.1.1. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

3.2.2. Top player positioning

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Surge in adoption of autoimmune disease therapeutics

3.3.1.2. Increase in incidence of autoimmune disease

3.3.1.3. Wide availibility of adavanced therapeutics

 

3.3.2. Restraints

 

3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics

 

3.3.3. Opportunities

 

3.3.3.1. Growth opportunities in emerging economies

3.3.3.2. Strong presence of pipeline drugs

 

3.3.4. Impact Analyses

 

CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Anti-inflammatory

 

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast

4.2.3. Market analysis, by country

 

4.3. Antihyperglycemics

 

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast

4.3.3. Market analysis, by country

 

4.4. NSAIDs

 

4.4.1 Key market trends, growth factors, and opportunities

4.4.2 Market size and forecast

4.4.3 Market analysis, by country

 

4.5 Interferons

 

4.5.1 Key market trends, growth factors, and opportunities

4.5.2 Market size and forecast

4.5.3 Market analysis, by country

 

4.6 Others

 

4.6.1. Key market trends, growth factors, and opportunities

4.6.2. Market size and forecast

4.6.3. Market analysis, by country

 

CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Rheumatic Disease

 

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

 

5.3. Type 1 Diabetes

 

5.3.1 Market size and forecast, by region

5.3.2 Market analysis, by country

 

5.4 Multiple Sclerosis

 

5.4.1 Market size and forecast, by region

5.4.2 Market analysis, by country

 

5.5 Inflammatory Bowel Disease

 

5.5.1 Market size and forecast, by region

5.5.2 Market analysis, by country

 

5.6 Others

 

5.6.1. Market size and forecast, by region

5.6.2. Market analysis, by country

 

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. Hospital pharmacy

 

6.2.1. Market size and forecast, by region

6.2.2. Market analysis, by country

 

6.3. Drug store & retail pharmacy

 

6.3.1. Market size and forecast, by region

6.3.2. Market analysis, by country

 

6.4. Online Store

 

6.4.1. Market size and forecast, by region

6.4.2. Market analysis, by country

 

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. North America market size and forecast, by country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class

6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication

6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication

6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication

6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel

 

6.2.3. North America market size and forecast, by drug class

6.5.4. North America market size and forecast, by indication

6.2.5. North America market size and forecast, by sales channel

 

6.3. Europe

 

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Europe market size and forecast, by country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication

6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel

 

6.3.2.2. France

 

6.3.2.2.1. France autoimmune disease therapeutics market, by drug class

6.2.2.1.2. France autoimmune disease therapeutics market, by indication

6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel

 

6.3.2.3. UK

 

6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class

6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication

6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication

6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication

6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication

6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel

 

6.3.3. Europe market size and forecast, by drug class

6.5.4. Europe market size and forecast, by indication

6.3.5. Europe market size and forecast, by sales channel

 

6.4. Asia-Pacific

 

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Asia-Pacific market size and forecast, by country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication

6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel

 

6.4.2.2. China

 

6.4.2.2.1. China autoimmune disease therapeutics market, by drug class

6.2.2.1.2. China autoimmune disease therapeutics market, by indication

6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication

6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel

 

6.4.2.4. India

 

6.4.2.4.1. India autoimmune disease therapeutics market, by drug class

6.2.2.1.2. India autoimmune disease therapeutics market, by indication

6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class

6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication

6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication

6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel

 

6.4.3. Asia-Pacific market size and forecast, by type

6.5.4. Asia-Pacific market size and forecast, by indication

6.4.5. Asia-Pacific market size and forecast, by sales channel

 

6.5. LAMEA

 

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. LAMEA market size and forecast, by country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication

6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication

6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class

6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication

6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel

 

6.5.2.4. Rest of LAMEA

 

6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication

6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel

 

6.5.3. LAMEA market size and forecast, by type

6.5.4. LAMEA market size and forecast, by indication

6.5.5. LAMEA market size and forecast, by sales channel

 

CHAPTER 7: COMPANY PROFILES

 

7.1. Abbott Laboratories

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

 

7.2. AbbVie Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

 

7.3. Amgen Inc.

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

 

7.4. AstraZeneca plc.

 

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

 

7.5. Bristol-Myers Squibb Company

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product Portfolio

7.5.5. Business performance

 

7.6. F. Hoffmann-La Roche AG

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product Portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

 

7.7. Johnson & Johnson

 

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

 

7.8. Novartis AG

 

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

 

7.9. Pfizer Inc.

 

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

 

7.10. UCB S.A.

 

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

7.10.6.Key strategic moves and developments

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025,"the global autoimmune disease therapeutics market was valued at USD 109,833 million in 2017, and is expected to reach USD 153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
 
Autoimmune disease therapeutics include different types of drugs such as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, immune suppressants, corticosteroids, beta-blockers, and others. The demand for autoimmune disease therapeutics is estimated to increase during the forecast period owing to surge in prevalence of autoimmune disease, advancement in screening & diagnosis procedures, and wide availability of advanced therapeutics. Moreover, strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others is expected to further boost the market growth.
 
Based on drug class, the global autoimmune disease therapeutics market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017, and is expected to maintain its dominance during the forecast period owing to increase in demand for anti- inflammatory drugs, launch of newer anti- inflammatory drugs with the supportive reimbursement policies for usage of advanced anti- inflammatory drugs in some countries. Moreover, expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab, and others, is estimated to further influence the market growth.
 
Based on indication, the market is classified as rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. Rheumatic disease segment accounted for a major share in 2017 and is expected to remain dominant during the forecast period owing to surge in prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, polymyalgia rheumatica and others, wide availability of advanced therapeutics for treatment of rheumatic disease, availability of advanced therapeutics for the treatment of these diseases.
 
According to sales channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online stores. Online providers segment is expected to experience rapid growth during the forecast period owing to rise in preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy with rise in number of internet users. On the other side, drug store & retail pharmacy segment is estimated to be the major revenue contributor due to massive presence of these pharmacies.
 
Key Findings of theAutoimmune Disease Therapeutics Market:
Based on indication, the rheumatic disease segment held nearly half of the global market share in 2017, and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
Based on sales channel, the online stores segment is expected to experience rapid growth and is projected to grow at a CAGR of 6.8% during the forecast period 2018-2025.
Depending on drug class, the anti-inflammatory segment accounted for nearly half of the global market share in 2017, and is projected to grow at a CAGR of 5.2% from 2018 to 2025.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.3% during the forecast period.
North America accounted for a major market share in 2017, and is expected to remain dominant throughout the forecast period. Higher prevalence of autoimmune disease, early diagnosis, easy availability of advanced therapeutics, strong presence of key players, favorable reimbursement in healthcare system, and higher number of trained medical professionals are key drivers of the North America autoimmune disease therapeutics market. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period owing to increase in number of target population, rise in adoption of therapeutics with development in healthcare infrastructure.
READ MORE

Scope

CHAPTER 1: INTRODUCTION

 

1.1. Report description

1.2. Key benefits for stakeholders

1.3. Key market segments

 

1.3.1. List of key players profiled in the report

 

1.4. Research methodology

 

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models

 

CHAPTER 2: EXECUTIVE SUMMARY

 

2.1. Key findings of the study

 

2.1.1. CXO perspective

 

CHAPTER 3: MARKET OVERVIEW

 

3.1. Market definition and scope

3.2. Key findings

 

3.2.1. Top investment pockets

3.2.2. Top player positioning

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Surge in adoption of autoimmune disease therapeutics

3.3.1.2. Increase in incidence of autoimmune disease

3.3.1.3. Wide availibility of adavanced therapeutics

 

3.3.2. Restraints

 

3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics

 

3.3.3. Opportunities

 

3.3.3.1. Growth opportunities in emerging economies

3.3.3.2. Strong presence of pipeline drugs

 

3.3.4. Impact Analyses

 

CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

 

4.1. Overview

 

4.1.1. Market size and forecast

 

4.2. Anti-inflammatory

 

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast

4.2.3. Market analysis, by country

 

4.3. Antihyperglycemics

 

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast

4.3.3. Market analysis, by country

 

4.4. NSAIDs

 

4.4.1 Key market trends, growth factors, and opportunities

4.4.2 Market size and forecast

4.4.3 Market analysis, by country

 

4.5 Interferons

 

4.5.1 Key market trends, growth factors, and opportunities

4.5.2 Market size and forecast

4.5.3 Market analysis, by country

 

4.6 Others

 

4.6.1. Key market trends, growth factors, and opportunities

4.6.2. Market size and forecast

4.6.3. Market analysis, by country

 

CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION

 

5.1. Overview

 

5.1.1. Market size and forecast

 

5.2. Rheumatic Disease

 

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

 

5.3. Type 1 Diabetes

 

5.3.1 Market size and forecast, by region

5.3.2 Market analysis, by country

 

5.4 Multiple Sclerosis

 

5.4.1 Market size and forecast, by region

5.4.2 Market analysis, by country

 

5.5 Inflammatory Bowel Disease

 

5.5.1 Market size and forecast, by region

5.5.2 Market analysis, by country

 

5.6 Others

 

5.6.1. Market size and forecast, by region

5.6.2. Market analysis, by country

 

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. Hospital pharmacy

 

6.2.1. Market size and forecast, by region

6.2.2. Market analysis, by country

 

6.3. Drug store & retail pharmacy

 

6.3.1. Market size and forecast, by region

6.3.2. Market analysis, by country

 

6.4. Online Store

 

6.4.1. Market size and forecast, by region

6.4.2. Market analysis, by country

 

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION

 

6.1. Overview

 

6.1.1. Market size and forecast

 

6.2. North America

 

6.2.1. Key market trends, growth factors, and opportunities

6.2.2. North America market size and forecast, by country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class

6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication

6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication

6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication

6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel

 

6.2.3. North America market size and forecast, by drug class

6.5.4. North America market size and forecast, by indication

6.2.5. North America market size and forecast, by sales channel

 

6.3. Europe

 

6.3.1. Key market trends, growth factors, and opportunities

6.3.2. Europe market size and forecast, by country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication

6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel

 

6.3.2.2. France

 

6.3.2.2.1. France autoimmune disease therapeutics market, by drug class

6.2.2.1.2. France autoimmune disease therapeutics market, by indication

6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel

 

6.3.2.3. UK

 

6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class

6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication

6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication

6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication

6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication

6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel

 

6.3.3. Europe market size and forecast, by drug class

6.5.4. Europe market size and forecast, by indication

6.3.5. Europe market size and forecast, by sales channel

 

6.4. Asia-Pacific

 

6.4.1. Key market trends, growth factors, and opportunities

6.4.2. Asia-Pacific market size and forecast, by country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication

6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel

 

6.4.2.2. China

 

6.4.2.2.1. China autoimmune disease therapeutics market, by drug class

6.2.2.1.2. China autoimmune disease therapeutics market, by indication

6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication

6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel

 

6.4.2.4. India

 

6.4.2.4.1. India autoimmune disease therapeutics market, by drug class

6.2.2.1.2. India autoimmune disease therapeutics market, by indication

6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class

6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication

6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication

6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel

 

6.4.3. Asia-Pacific market size and forecast, by type

6.5.4. Asia-Pacific market size and forecast, by indication

6.4.5. Asia-Pacific market size and forecast, by sales channel

 

6.5. LAMEA

 

6.5.1. Key market trends, growth factors, and opportunities

6.5.2. LAMEA market size and forecast, by country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication

6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication

6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class

6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication

6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel

 

6.5.2.4. Rest of LAMEA

 

6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class

6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication

6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel

 

6.5.3. LAMEA market size and forecast, by type

6.5.4. LAMEA market size and forecast, by indication

6.5.5. LAMEA market size and forecast, by sales channel

 

CHAPTER 7: COMPANY PROFILES

 

7.1. Abbott Laboratories

 

7.1.1. Company overview

7.1.2. Company snapshot

7.1.3. Operating business segments

7.1.4. Product Portfolio

7.1.5. Business performance

 

7.2. AbbVie Inc.

 

7.2.1. Company overview

7.2.2. Company snapshot

7.2.3. Operating business segments

7.2.4. Product portfolio

7.2.5. Business performance

7.2.6. Key strategic moves and developments

 

7.3. Amgen Inc.

 

7.3.1. Company overview

7.3.2. Company snapshot

7.3.3. Operating business segments

7.3.4. Product Portfolio

7.3.5. Business performance

 

7.4. AstraZeneca plc.

 

7.4.1. Company overview

7.4.2. Company snapshot

7.4.3. Operating business segments

7.4.4. Product portfolio

7.4.5. Business performance

 

7.5. Bristol-Myers Squibb Company

 

7.5.1. Company overview

7.5.2. Company snapshot

7.5.3. Operating business segments

7.5.4. Product Portfolio

7.5.5. Business performance

 

7.6. F. Hoffmann-La Roche AG

 

7.6.1. Company overview

7.6.2. Company snapshot

7.6.3. Operating business segments

7.6.4. Product Portfolio

7.6.5. Business performance

7.6.6. Key strategic moves and developments

 

7.7. Johnson & Johnson

 

7.7.1. Company overview

7.7.2. Company snapshot

7.7.3. Operating business segments

7.7.4. Product Portfolio

7.7.5. Business performance

 

7.8. Novartis AG

 

7.8.1. Company overview

7.8.2. Company snapshot

7.8.3. Operating business segments

7.8.4. Product Portfolio

7.8.5. Business performance

7.8.6. Key strategic moves and developments

 

7.9. Pfizer Inc.

 

7.9.1. Company overview

7.9.2. Company snapshot

7.9.3. Operating business segments

7.9.4. Product Portfolio

7.9.5. Business performance

 

7.10. UCB S.A.

 

7.10.1. Company overview

7.10.2. Company snapshot

7.10.3. Operating business segments

7.10.4. Product Portfolio

7.10.5. Business performance

7.10.6.Key strategic moves and developments

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS